Holen Sie sich die Stockscreener-App
15.30
3.03%
0.45
Handel nachbörslich:
15.40
0.10
+0.65%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits
Why Ultragenyx Pharmaceutical (RARE) Is Down 40.3% After Angelman Trial Failure And Cost-Cut Plan - Yahoo Finance
Ultragenyx (RARE) Stock Looks Fully Valued Following Its Phase 3 Setback - Yahoo Finance
Ionis Pharma prices first FDA-approved treatment for Alexander disease at $285,000 per dose - Reuters
RARE Stock Plunges As Ultragenyx Misses Key GTX-102 Trial - StocksToTrade
Ultragenyx Stock Crashes After GTX-102 Failure Despite Genglycos Win - timothysykes.com
Ultragenyx Stock Crashes As GTX-102 Failure Erases Optimism - StocksToTrade
RARE Stock Crashes As Ultragenyx Faces GTX-102 Trial Failure - timothysykes.com
The Goldman Sachs Group Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap UpTime to Buy? - MarketBeat
Rx Rundown: Eli Lilly, Ultragenyx, Novartis and more - Medical Marketing and Media
Barclays Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Lowered to "Hold" at Royal Bank Of Canada - MarketBeat
Wellington Management Group LLP Reduces Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout - Yahoo Finance
Ultragenyx: A 44% Crash After Trial Failure, Two Weeks After First Gene Therapy Approval - Kavout
Ultragenyx Pharmaceutical (RARE) Reports 61% Cornstarch Reduction In 96 Week Phase 3 Data - simplywall.st
Ultragenyx vows 'significant' cuts after experimental rare-disease drug flunks late-stage clinical trial - The Business Journals
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $28.00 by Analysts at Jefferies Financial Group - MarketBeat
Ultragenyx: Angelman Study Setback Creates More Risk For Rare Disease Specialist - Seeking Alpha
Ultragenyx's Apazunersen Fails Phase III Trial | PharmExec - Pharmaceutical Executive
Ultragenyx Shares Crater After Angelman Syndrome Drug Fails Pivotal Trial - finance.biggo.com
Ultragenyx Trial Failure Revives Debate About How to Treat a Rare Neuro Disorder - MedCity News
Ultragenyx Pharmaceutical Target of Unusually Large Options Trading (NASDAQ:RARE) - MarketBeat
Ultragenyx Weighs Future of Angelman Syndrome ASO After Phase III Trial Failure - GenomeWeb
Citigroup Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline - Barron's
Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A TargetUltragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $18.00 Price Target at TD Cowen - MarketBeat
Angelman wings clipped by Ultragenyx phase III bust - BioWorld News
Ultragenyx's Apazunersen Fails Phase 3 Angelman Syndrome Trial - BioPharm International
Ultragenyx mulls fate of rare disease programme on Phase III flop - Clinical Trials Arena
Ultragenyx stock downgraded after trial setback (RARE:NASDAQ) - Seeking Alpha
Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report? - Yahoo Finance
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals - TradingView
Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study - BioPharma Dive
Ultragenyx Pharmaceutical Inc. (RARE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Ultragenyx sinks as Phase 3 Angelman trial miss slams a key pipeline bet - Quiver Quantitative
Ultragenyx Pharmaceutical (NASDAQ:RARE) Downgraded to "Neutral" Rating by Bank of America - MarketBeat
Ultragenyx Shares Drop Following Failed Phase III Clinical Trial - Pharmaceutical Executive
Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 12-Month Low After Analyst Downgrade - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $37.00 Price Target at Canaccord Genuity Group - MarketBeat
Ultragenyx to slash costs after Angelman trial failure - pharmaphorum
We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more - STAT
RARE Stock Craters As Ultragenyx Slashes Outlook After Trial Failure - timothysykes.com
RARE Stock Craters As Aspire Trial Failure Triggers Reset - StocksToTrade
William Blair Downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) to Market Perform - MarketBeat
Why Is Ultragenyx Stock Tumbling Today?Ultragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga
RARE Stock Collapses After Angelman Drug Fails Late-Stage Trial - StocksToTrade
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Lowered to $33.00 at Cantor Fitzgerald - MarketBeat
HC Wainwright Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Lowered to Neutral Rating by JPMorgan Chase & Co. - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Lowered to In-Line at Evercore - MarketBeat
Ultragenyx Angelman syndrome drug fails Phase III test - The Pharma Letter
Ultragenyx’s ‘high-risk’ Angelman bet fails, cratering stock and forcing strategic review - BioSpace
Wells Fargo cuts Ultragenyx Pharma price target on trial failure By Investing.com - Investing.com South Africa
William Blair Downgrades Ultragenyx Pharmaceutical to Market Perform From Outperform - marketscreener.com
Evercore ISI Downgrades Ultragenyx Pharmaceutical to In Line From Outperform, Adjusts Price Target to $16 From $34 - marketscreener.com
Baird Downgrades Ultragenyx Pharmaceutical to Neutral From Outperform, Adjusts Price Target to $16 From $40 - marketscreener.com
Wells Fargo cuts Ultragenyx Pharma price target on trial failure - Investing.com
Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial - marketscreener.com
JPMorgan cuts Ultragenyx stock rating on trial setback - Investing.com
Baird cuts Ultragenyx stock rating on failed Angelman trial - Investing.com
Ultragenyx's Angelman syndrome drug fails pivotal Phase 3 trial - app.dealroom.co
Ultragenyx drops on Phase 3 trial failure for Angelman syndrome drug (RARE:NASDAQ) - Seeking Alpha
Ultragenyx's ASO fails in Angelman syndrome, triggering sell-off - FirstWord Pharma
Ultragenyx drug fails phase 3 trial for Angelman syndrome - Investing.com
Ultragenyx stock plunges 40% on failed Angelman trial - Investing.com
Ultragenyx: Phase 3 Aspire for apazunersen misses primary and key secondary endpoints - TradingView
A drug trial missed both goals. Angelman syndrome has no approved treatment. - Stock Titan
Ultragenyx Publishes 96-Week GENGLYCOS Gene Therapy Data for Glycogen Storage Disease - BioPharm International
Royal Bank of Canada Reduces Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical (RARE) Wins FDA Approval, Is The Stock Fully Priced? - Yahoo Finance
Ultragenyx Pharmaceutical Inc. Publishes 96-Week Phase 3 Data For GENGLYCOS AAV Gene Therapy In GSDIa - marketscreener.com
Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease - GlobeNewswire
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Corient Private Wealth LP Acquires New Shares in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):